Neurocrine Biosciences, Inc. (NBIX)
| Market Cap | 13.25B +32.8% |
| Revenue (ttm) | 2.86B +21.4% |
| Net Income | 478.60M +40.2% |
| EPS | 4.67 +41.9% |
| Shares Out | 100.58M |
| PE Ratio | 28.22 |
| Forward PE | 14.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 679,466 |
| Open | 131.79 |
| Previous Close | 131.67 |
| Day's Range | 129.86 - 132.41 |
| 52-Week Range | 105.45 - 160.18 |
| Beta | 0.34 |
| Analysts | Strong Buy |
| Price Target | 180.91 (+37.28%) |
| Earnings Date | May 5, 2026 |
About NBIX
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo... [Read more]
Financial Performance
In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for NBIX stock is "Strong Buy." The 12-month stock price target is $180.91, which is an increase of 37.28% from the latest price.
News
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
At two years, 60% of patients who were overweight or obese at baseline experienced clinically meaningful improvements in body mass index, and 61% of those with insulin resistance at baseline were no l...
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
Research published in The Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA® (valbenazine) capsules across the KINECT® clinical program Publication establishes a ...
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Approximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologic‑range glucocorticoid dosing at two years 75% of patients originally taking dexamethasone transitioned off...
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Tuesday, May 5 SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2...
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
INGREZZA showed higher rates of long-term treatment continuation and lower switching between medications compared to AUSTEDO XR (deutetrabenazine) in a real-world claims analysis among adults with tar...
Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
Tokyo, Japan and Cambridge, UK, 13 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a...
Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover
Soleno Therapeutics said on Tuesday it has voluntarily withdrawn the European marketing application for its rare metabolic disorder drug following acquirer Neurocrine's plans to sharpen focus on the...
Neurocrine Biosciences Transcript: M&A announcement
The acquisition adds a first-in-class rare disease therapy, VYKAT XR, to the portfolio, accelerating revenue growth and diversification. The $2.9B all-cash deal is expected to be accretive in 2026, with strong IP protection and a focus on U.S. market expansion.
Neurocrine to Buy Soleno for $2.9 Billion
Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion in a move intended to expand its endocrinology and rare-disease portfolio.
This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal.
Neurocrine Biosciences stock fell after the merger was announced.
Neurocrine to buy Soleno Therapeutics for $2.9 billion
Neurocrine Biosciences will acquire rare disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday.
Neurocrine wants to develop new obesity drugs. It's reportedly nearing an acquisition to accelerate that move.
Soleno Therapeutics stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the company.
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercia...
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
Expert panel establishes structured approach to tardive dyskinesia screening, diagnosis and treatment in long-term care, including use of VMAT2 inhibitors New post-hoc KINECT‑PRO™ analysis in adults a...
Neurocrine Biosciences Transcript: Stifel 2026 Virtual CNS Forum
Revenue grew 22% last year, driven by Ingrezza and CRENESSITY, with strong guidance for 2026 and ongoing sales force expansion. Multiple phase II/III readouts are expected in 2027, including neuropsychiatry and next-gen VMAT2 programs, while pricing and access remain stable amid regulatory changes.
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Opera...
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
SAN DIEGO, March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum at 4:30 ...
Neurocrine Biosciences Transcript: Leerink Global Healthcare Conference 2026
Two approved products are fueling strong growth, with CRENESSITY’s rare disease launch among the top 10% historically and INGREZZA targeting nearly 10% annual growth. R&D investment remains high, supporting late-stage trials and new obesity initiatives, while financials show robust cash, no debt, and strong profitability.
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
TROY, Mich., March 6, 2026 /PRNewswire/ -- Equifax Inc.'s recent report has investors wondering if the company's stock is fairly valued.
Neurocrine Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Strong commercial momentum for INGREZZA and CRENESSITY underpins financial strength and growth, with both products expected to drive double-digit volume increases. R&D strategy targets CNS leadership, diversified modalities, and a robust obesity pipeline, with key data expected in 2026.
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: TD Cowe...
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance
Neurocrine Biosciences Inc (NASDAQ: NBIX) on Wednesday reported fourth-quarter adjusted earnings of $1.88 per share, missing the consensus of $1.89.
Neurocrine Biosciences Earnings Call Transcript: Q4 2025
2025 saw 22% sales growth to $2.8B, led by INGREZZA and CRENESSITY, with strong cash flow and operating margins. INGREZZA is set for 10% growth in 2026, while CRENESSITY reached 10% CAH market penetration in its first year. Pipeline and sales force expansions support continued momentum.
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion, Representing Year-Over-Year Growth of 29% and 22%, Respectively INGREZZA® (valbenazine) Full Year 2026 Ne...
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
SAN DIEGO, Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with...